ReviewTherapeutic advances in vaccines and immunotherapy2025
Cervical cancer trends, HPV vaccine utilization, and screening in low- and lower-middle-income countries: an updated review.
Review in Therapeutic advances in vaccines and immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Strategies implemented to increase HPV vaccine uptake and confidence among men who have sex with men and transgender people: A systematic review.Human vaccines & immunotherapeutics · 2026Pooled it
- Cytotoxic Activity of Halymenia durvillaei against Cervical Cancer Cells: In Vitro and Computational Evidence.Cell biochemistry and biophysics · 2026Article
- An end-to-end quality assurance procedure for pelvic VMAT using optically stimulated luminescence dosimeters and an anthropomorphic phantom.Physical and engineering sciences in medicine · 2026Article
- Immunological Determinants of Oncogenic Virus-Driven Cancers in Africa: Mechanisms, Co-Infections and Public Health Challenges.Pathogens (Basel, Switzerland) · 2026Review
- Knowledge and Awareness of HPV, the HPV Vaccine, and Cervical Cancer Among Women From a Brazilian Community: A Community-Based Cross-Sectional Study.Health science reports · 2026Article
- Factors associated with cervical cancer screening in the South African demographic and health survey.Cancer causes & control : CCC · 2026Article
- Pakistan's 2025 HPV Vaccine Phase I Rollout: Community Response, Implementation Challenges & Way Forward.Vaccines · 2026Article
- PREVALENCE, CHARACTERISTICS AND TREATMENT OUTCOMES OF HPV POSITIVE OROPHARYNGEAL CARCINOMA IN AFRICA: A SYSTEMATIC REVIEW AND META-ANALYaSIS.Annals of Ibadan postgraduate medicine · 2026Article
- Article
- Yttrium oxide nanoparticles induce potent selective cytotoxicity in HeLa cervical cance cells through ROS-mediated genomic instability and mitochondrial apoptosis.Scientific reports · 2026Article
- Cervical Cancer Epidemiology: Global Incidence, Mortality, Survival, Risk Factors, and Equity in HPV Screening and Vaccination.Journal of clinical medicine · 2026Review
- Determinants of cervical cancer screening among women living with HIV in Lesotho using nationally representative 2023/24 DHS data.Scientific reports · 2026Article
- Integrative network pharmacology, molecular dynamics simulation, and single-cell RNA sequencing strategies reveal the multi-target mechanisms of oridonin against cervical cancer.Frontiers in pharmacology · 2026Article
- Evaluation of HPV Knowledge Levels Among Healthcare Professionals and Medical Students: A Multicenter Cross-Sectional Study in Private Hospitals and Foundation Universities in Turkey.Obstetrics and gynecology international · 2026Article
- Marginalized voices on HPV vaccination in India: exploring knowledge, attitudes, and acceptance.Frontiers in global women's health · 2026Article
- Optimized ultrasound extraction and cytotoxic activity against HeLa cervical cancer cells of total flavonoids ofFrontiers in pharmacology · 2026Article
- Evaluation of Antiproliferative Activity and Molecular Modeling Studies of Some Novel Benzimidazolone-Bridged Hybrid Compounds.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Outcomes of Cervical Cancer Treatment Using Total Mesometrial Resection (TMMR) Performed with the Robotic System-A Preliminary Report.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer is the fourth most common cancer among women worldwide, with 660,000 new cases and 350,000 deaths reported in 2022. This disease mainly affects women in low- and lower-middle-income countries (LMICs), where 90% of cases occur. This study explored how LMICs are responding to the World Health Organization's (WHO) call to eliminate cervical cancer. It looked at cervical cancer rates, the use of human papillomavirus (HPV) vaccines, and suggested strategies to fight the disease. The study analyzed the rates of cervical cancer and deaths in LMICs, the effectiveness of HPV vaccination programs, and how well screening efforts are working. To compare data across countries, it used age-standardized incidence rates (ASIRs) and age-standardized mortality rates (ASMRs) per 100,000 women per year. In 2022, the ASIR was 25.4% in lower income countries and 16.9% in lower-middle-income countries. The ASMR was also higher in lower income countries (18.5%) compared to lower-middle-income countries (10.3%). HPV vaccine coverage remains low in many LMICs, with significant differences between the rates of first and final doses completed. By 2050, the number of new cervical cancer cases is expected to rise. Although the WHO aims to eliminate cervical cancer by achieving 90% HPV vaccination by age 15, 70% screening coverage, and 90% access to treatment, many challenges remain in LMICs. These include weak healthcare systems, poor infrastructure, and a lack of health education. Overcoming these challenges through better vaccine distribution, improved screening programs, and stronger healthcare systems is essential to eliminate cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.